Kornimate/medical-research-clean huggingface dataset:
gait characteristics and cognitive evolution in parkinson disease

Conditions: Parkinson's Disease

Summary: parkinson's disease (pd) is a chronic progressive nervous system disease with gradual motor impairment. cognitive dysfunction is common in pd, even in the early stages, and it is characterized by impairments in executive, attention, memory, language and visuospatial function. motor symptoms, in particular, alterations in gait, have been studied in clinical practice to assess disease progression, and its response to treatments, both farmacological and physiotherapeutic. recent research on wearable technology in pd has shown that motor tests can be automated using wearable technology to eliminate human supervision and patient-reported data. particularly, the quantitative gait analysis by using inertial devices has been proposed as a sensitive tool to longitudinally monitor gait worsening, response to dopaminergic treatment over time and cognitive dysfunction in pd patients. the aim of this prospective multicente observational study is to investigate whether the dysfunction of specific gait parameters may be correlated to cognitive impairment (attention/executive function domain) in a cohort of ambulatory pd patients followed for 3 years.

this is a prospective multicenter observational study with annual follow-up assessments over 3 years. gait is assessed by an inertial device (bts g-walk). g- walk is an easy-to-use solution to obtain accurate, objective and quantitative spatial-temporal gait data. the device is a wireless system consisting of an inertial sensor composed by a triaxial accelerometer, a magnetic sensor, and a triaxial gyroscope that positioned on lumbar/ or sacral segments allows a functional gait analysis. cognitive performance is evaluated with a neuropsychological battery designed to assess memory, executive /attention, and visuospatial domains.

Eligibility criteria:
inclusion criteria: * both sex * aged between 55-74 years * diagnosis of idiopathic pd based on mds clinical diagnostic criteria * hoehn \& yahr (h\&y) stages 2 to 3 at enrollment, independently by pd duration * clinical-pharmacological stabilization until 3 months before the enrollment * dbs treatment (stable stimulation parameters until 6 months before the enrollment) exclusion criteria: * evidence of neurodegenerative and secondary parkinsonism * dementia ( (score \<25 on the mini mental state examination - mmse) * psychiatric disorder (beck depression inventory-ii - bdi-ii score \>19) * presence of organ failure (modified cumulative illness rating scale - cirs \> 2) * orthopedic disorder or co-morbidities that may affect gait * drug and alcohol use

Keywords: gait attention/executive function domain device walk parameters wireless inertial sensor
female urogenital nutrition- health study

Conditions: Bacterial Urinary Tract Infection

Summary: the purpose of this study is to assess nutrition and urinary tract bacterial activity during menstruation of approximately 15 female university reserve officer training corps (rotc) cadets and phoenix area police officers, firefighters, and military veterans.

urinary tract infections (utis) disrupt tactical service women's obligations and health, which increases sexual transmitted infections (stis), hpv, and cervical cancer risk if left untreated. females are more susceptible to utis due to their unique anatomical features and hormone fluctuations affecting vaginal flora. during phase 1 of the menstrual cycle (i.e., onset of bleeding, menstrual cycle days 1-5), estrogen levels significantly decrease and inhibit the growth of lactobacilli (good bacteria), which is essential in warding off bad bacteria and infections, particularly utis. the uropathogenic bacterial growth in phase 1 could be heightened in phase 2 of the menstrual cycle (i.e., leading to ovulation), as increases in estrogen favors bacteria adhesion and arginine vasopressin (avp) release that stimulates fluid retention, leading to less volume flow in the urinary tract. to reduce uti onset, it is recommended to frequently urinate with sufficient urine void volume to facilitate washing out harmful bacteria from the urethra and bladder. while menstruating, increased fluid consumption to support urination frequency and void volume may be critical, as the urinary tract is more predisposed to infections, and the effects of estrogen on bacterial adhesion and avp release in phase 2 could continue uropathogenic growth. question(s) 1: are premenopausal tactical service women's current hydration status and behaviors (i.e., fluid intake and urination) sufficient? how many premenopausal tactical service women have a uti history? question 2: will increasing daily water intake of identified underhydrated tactical service women reduce uropathogenic bacterial activity during the first part (i.e., onset of bleeding through day 5) of the menstrual cycle?

Eligibility criteria:
inclusion criteria: * female * 18-34 years of age or older (premenopausal) * have a 21-35-day menstrual cycle * no changes in hormonal contraceptives within the last three months * no current uti symptoms * sexual activity and inactivity exclusion criteria: * males * under 18 years of age or over 34 years of age * pregnant or nursing * menstrual irregularities effecting having a menstrual cycle to be between 21-35 days * progesterone-only contraceptive use (combined estrogen-progesterone and non-hormonal iuds are okay) * currently taking antibiotics * on hormone replacement therapy * currently experiencing symptomatic vulvovaginitis * diagnosed with recurrent uti * not volunteering to participate
balance and muscle strength as indicators of fracture risk in postmenopausal women

Conditions: Osteoporosis

Summary: the study is designed as a cross-sectional clinical study. a total of 156 postmenopausal women who visited the physical therapy and rehabilitation outpatient clinic at beylikdüzü state hospital and have had dual x-ray absorptiometry (dxa) measurements taken within the last 6 months will be included. the sociodemographic data of the patients will be recorded. femoral neck and lumbar l1-l4 t-scores and femoral neck bone mineral density (bmd) values obtained from dxa measurements will be collected. to calculate fracture risk, the percentages for major and hip fracture risks will be calculated using the fracture risk assessment tool (frax®). the one-leg stance test, used to assess static posture and balance, and the 30-second sit-to-stand test, used to evaluate endurance and lower extremity strength, will be applied to the patients.

this study is designed as a cross-sectional clinical investigation aimed at assessing fracture risk in postmenopausal women. a total of 156 postmenopausal women who attended the physical therapy and rehabilitation outpatient clinic at beylikdüzü state hospital and had undergone dual x-ray absorptiometry (dxa) measurements within the past six months will be included. sociodemographic data, such as age, weight, height, and medical history, will be recorded for each participant. the study will gather femoral neck and lumbar l1-l4 t-scores, as well as femoral neck bone mineral density (bmd) values, obtained from dxa scans. to evaluate the risk of fractures, major and hip fracture percentages will be calculated using the fracture risk assessment tool (frax®), a widely accepted method for predicting fracture risk in osteoporosis patients. two functional tests will be applied: the one-leg stance test, which measures static balance and postural stability, and the 30-second sit-to-stand test, which assesses lower extremity strength and endurance. these simple, quick tests will be used to determine whether they can serve as practical predictors of fracture risk in postmenopausal patients. the study aims to evaluate whether these two functional tests can provide rapid and effective fracture risk assessments in clinical practice, offering a valuable tool for clinicians in identifying high-risk patients early and implementing preventive measures.

Eligibility criteria:
inclusion criteria: * being a postmenopausal woman over the age of 50, * agreeing to participate in the study, * having no conditions that would prevent the individual from performing the tests to be administered during the study. exclusion criteria: * refusal to participate, * presence of neuromuscular or cardiac diseases that would prevent the performance of the tests, * psychiatric disorders, * cognitive impairments, * uncontrolled hypertension, * use of medications that could affect the study results.
treatment of gastric peritoneal carcinomatosis by association of complete surgical resection of the lesions and intraperitoneal immunotherapy using catumaxomab

Conditions: Patients With Gastric Peritoneal Carcinomatosis

Summary: treatment by association of complete surgical excision of the lesions and intraperitoneal immunotherapy using catumaxomab for patients with gastric peritoneal carcinomatosis


Eligibility criteria:
inclusion criteria: * consent form signed * age \>= 18 * carcinomatosis pre operative known or discivered in intraoperative * patients uin good general condition who may have extent surgery associated to specific inflammatory syndrom of immunotherapy * patients in good general condition * patient insured to social care inclusion criteria (intraoperative): * gastric adenocarcinoma with macroscopic peritoneal carcinomatosis (pc) confirmed by extemporaneous histological examination * cp extension minimal or moderate (peritoneal index ≤ 12). * resection of the entire macroscopic lesions detectable (primary tumor, lymph nodes and cp). cleaning d2 lymph node (or d1.5). exclusion criteria: * presence of metastasis in reach * previous treatment with a non-humanized monoclonal ac- (mice or rat) * hypersensitivity to any type of antibody. * history of cancer within 5 years preceding the entry in the trial other than basal cell skin carcinoma or in situ of the cervix, * patients already included in another clinical trial with experimental molecule * pregnant, or likely to be or breastfeeding, (women of childbearing potential should have a pregnancy test (blood) negative 15 days before the date of the surgery) using of a suitable method of contraception for patients of childbearing age during treatment. adequate contraception methods includeare: an intrauterine device, hormonal contraception, condom use combined with a spermicide * persons deprived of liberty or trust (including curatorship) * unable to undergo medical test for geographical, social or psychological. exclusion criteria (intraoperative): * persistent peritoneal lesions visible to the end of the surgery * resection of the tail of the pancreas or pancreatic break (because no drainage post-op); break pleural (for k cardia) * presence of metastasis in reach during surgery (except for ovarian metastasis
re-engineered discharge for diabetes-computer adaptive testing (redd-cat)

Conditions: Diabetes Mellitus, Type 2

Summary: over 27 million americans are diagnosed with type 2 diabetes mellitus (t2dm), and their health outcomes, including hospitalization, emergency department use, and hospital readmission, are largely driven by social determinants; diabetes complications are largely attributable to unmet health-related social needs. investigators will conduct a pilot feasibility trial of the re-engineered discharge for diabetes-computer adaptive testing (redd-cat) system to inform the design of a future, fully-powered randomized controlled trial. redd-cat will allow clinical staff to preemptively link patients with community-based social services tailored to meet their unique needs in order to reduce avoidable hospitalization and emergency department visits.

investigators will conduct a pilot study with 30 patients to evaluate the feasibility and limited efficacy of the redd-cat social service screening and referral intervention to inform the design of a fully-powered trial. the study will determine the feasibility of delivering the redd-cat intervention in a clinical, point-of-care context to inform the design and implementation strategy for a fully powered clinical trial. it is not the purpose of this pilot clinical trial to determine sample size for a larger, fully-powered trial, as investigators already have data from prior readmissions research supporting sample size and power estimates using readmission rates as a primary outcome measure. after obtaining informed consent from a participant and gathering baseline data, the study research assistant (ra) will send a flag in the electronic medical record (emr) to notify the nurse care manager that a patient has enrolled in the redd-cat pilot. the nurse care manager will then incorporate the administration of the redd-cat to the patient as part of standard care discharge planning. he or she will utilize the redd-cat results report as a guideline for generating appropriate referrals to address unmet social needs identified. to inform secondary measure selection for a future larger study, the ra will administer to enrolled patients a number of standardized measures, including the phq-9, gad-7, ways of coping questionnaire, and diabetes distress scale. all baseline measures will be re-administered at 30-day follow-up to patients via the telephone. data on hospitalizations and ed visits during the 30-day period post-discharge will be obtained from patients' medical records, and all data gathered will be stored in a redcap electronic database.

Eligibility criteria:
inclusion criteria: * boston medical center inpatient * lives in the greater boston area * diagnosis of type 2 diabetes * english- speaking * demonstrated willingness and capacity to consent * age 18 or older * has reliable telephone access exclusion criteria: * currently pregnant * has plans to leave the area for \>2 weeks in the 45 days following enrollment in the study * diagnosis of dementia, memory loss, or memory deficit

Keywords: diabetes mellitus, type 2 social determinants readmission
treatment of social phobia with combined cognitive bias modification and icbt

Conditions: Social Phobia

Summary: the purpose of this study is to determine whether an internet-based treatment program, consisting of combined cognitive bias modification and cognitive behavioral therapy, reduces symptoms of social phobia among a population diagnosed with this disorder.

previous studies have shown that individuals with social phobia have attention biases, often focusing on or avoiding aversive stimuli (such as judging facial expressions) and thereby reinforcing the bias. computerized training programs have been developed to implicitly direct the users attention. in this study, such a program -- combined with an established, well-researched and proven effective form of internet-based cognitive behavioral therapy (icbt) -- will be provided to 128 participants that meet the diagnostic criteria for social phobia, and the pre/post-measurements will be compared. participants will be randomized to one of two groups, receiving one of two variants of the cognitive bias modification program (both receive icbt).

Eligibility criteria:
inclusion criteria: * written informed consent provided * diagnosed social phobia (according to dsm-iv criteria) * access to computer with internet connection exclusion criteria: * severe depression (and/or suicidal behavior) * suffer from other severe psychiatric condition (e.g. psychosis) * non-stable use of medication (3 months stable dosage) * undergoing other, parallel psychological treatment

Keywords: social phobia social anxiety cognitive bias modification
methylphenidate to improve balance and walking in ms

Conditions: Multiple Sclerosis

Summary: methylphenidate is an amphetamine-like psychomotor stimulant drug currently approved for the treatment of attention-deficit hyperactivity disorder (adhd), postural orthostasis tachycardia syndrome and narcolepsy. it is also often prescribed off label to people with ms to improve fatigue. it is proposed that methylphenidate may also improve imbalance and walking deficits in ms by improving concentration and central integration, one of the primary mechanisms thought to underlie imbalance and walking deficits in ms.

the proposed pilot study will examine the effects of methylphenidate on imbalance and walking in 24 subjects with ms and imbalance. the subjects will be randomly assigned to receive either an escalating does of methylphenidate, 20mg, 40mg or 60mg, divided into two doses each day, or matched placebo for 2 weeks at each dose. if a subject does not tolerate dose escalation they will be instructed to discontinue use of the drug. the maximum safely tolerated dose for each subject will be noted. changes from baseline in subject's walking speed, balance, vestibular function, cognitive function, and fatigue will be assessed at each dose.

Eligibility criteria:
inclusion criteria: * age 20-65 * able to walk at least 100m without an aide or with unilateral assistance * poor static balance, specifically prolonged apr latencies (≥ 1 standard deviation (sd) \> mean for healthy people in this age range), or * reduced balance-related activity (abc scores ≤ 85%) * walking difficulties, specifically t25fw \> 6 seconds, or reduced self perceived walking (msws-12 scores ≥ 50/60) exclusion criteria: * currently taking methylphenidate, modafinil, or armodafinil.(any within the last 2 weeks) * cause(s) of imbalance other than ms * systolic pressure consistently greater than 150 mm hg or diastolic pressure consistently greater than 90 mm hg * contraindications to methylphenidate (anxiety, tension, agitation, thyrotoxicosis, tachyarrhythmias, severe angina pectoris or glaucoma, hypersensitivity to methylphenidate, motor tics or a family history or diagnosis of tourette's syndrome, seizures, severe or poorly controlled hypertension, treatment with monoamine oxidase inhibitors currently or within the last 14 days, current use of guanethidine, pressors, coumarin anticoagulants, anticonvulsants, phenylbutazone, or tricyclic antidepressants, history of drug abuse or alcoholism) * pregnancy or breastfeeding

Keywords: multiple sclerosis postural balance walking
ocular comfort and the "aging" lens (erbium)

Conditions: Refractive Error

Summary: the purpose of this trial was to evaluate the factors affecting comfortable contact lens wear and how those factors affect contact lens replacement frequency.

eligible participants began phase 1, following either cycle a or cycle b, and crossing over to the second cycle after completing the first. after the phase 1 results were evaluated, eligible participants entered phase 2. after phase 2 results were evaluated, participants who consistently reported the highest and the lowest comfort scores entered phase 3 and were defined as either survivors or strugglers.

Eligibility criteria:
inclusion criteria: * at least 17 years of age. * ocular exam in the last two years. * currently wearing hydrogel or silicone hydrogel contact lenses on a daily wear basis with a monthly replacement schedule. * wearing contact lenses at least five days per week for a minimum of 10 hours each day. * able to wear lenses in the available power range with a best-corrected visual acuity of at least 20/32 in both eyes. * other protocol-defined inclusion criteria may apply. exclusion criteria: * any ocular disease. * systemic condition that may affect a study outcome. * using any systemic or topical medications that may affect ocular health. * wears lenses on an extended or continuous wear schedule. * habitually wears multifocal lenses. * other protocol-defined exclusion criteria may apply.
magnetic resonance flow measurements of mesenteric arteries and veins and portal vein

Conditions: Ischemia; Oxygen Deficiency

Summary: to determine the difference in baseline mr flow measurements and post-prandial mr flow measurements between patients diagnosed with cgi and patients not diagnosed with cgi.

the diagnosis of chronic gastro-intestinal ischemia (cgi) remains a clinical challenge because this diagnosis is difficult to distinguish by the frequent incidence of chronic abdominal pain and asymptomatic stenosis of the mesenteric arteries1. the standard diagnostic work up includes medical history, anamnesis and physical examination, radiological imaging and a functional test as visible light spectroscopy (vls)2-4 or tonometry5-7. a multidisciplinary team consisting of a gastroenterologist, a vascular surgeon and an interventional radiologist, all specialized in cgi, discusses all patients which results in an expert based consensus diagnosis. currently, there is no specific test to diagnose cgi. in literature, magnetic resonance (mr) techniques are described by which the flow in the mesenteric vessels is measured pre- and post-prandial in healthy volunteers and cgi patients8-12. the flow in the mesenteric vessels increases post-prandial (hyperemia). however, this increase in post-prandial flow compared to pre-prandial appeared less in cgi patients compared to the healthy volunteers. in some cgi patients, even a decrease of the post-prandial compared to pre-prandial flow was seen. we might be able to distinguish patients with cgi from patients without cgi with mr flow measurements with food stimulation.

Eligibility criteria:
inclusion criteria: 1. patients suspected of cgi referred to our hospital for further analysis 2. age ≥ 18 years 3. patients who gave informed consent exclusion criteria: 1. age \< 18 years 2. unable to give informed consent 3. pregnancy 4. contra-indications for mri: a. metal implants which cannot be removed. e.g. cardiac pacemakers/icd, aneurysm clips, metal stents, artificial heart valve, cochlea/retinal implants, hearing aids, dentures with magnetic click system or with other metal accessories, tattoos with metallic dye, metal plates/pins/screws of bones, piercings b. claustrophobia c. inability to lie still for 1 hour to 1,5 hours 5. other criteria the physician considers are not compatible with this study

Keywords: chronic gastro-intestinal ischemia oxygen deficiency of the gastro-intestinal tract